Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 216

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 216
---
 S-K and do not reflect the total compensation actually realized or received by Christopher Anzalone or the other NEOs on average, as applicable. In accordance with these rules, these amounts reflect “Total Compensation” as set forth in the Summary Compensation Table for each year, adjusted as shown below. Equity values are calculated in accordance with FASB ASC Topic 718, and the valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. Table of Contents 2025 PROXY STATEMENT Executive Compensation 53

Compensation Actually Paid 2024 2023 2022 2021 PEO Other NEOs* PEO Other NEOs* PEO Other NEOs* PEO Other NEOs* Summary Compensation Table Total $ 12,423,473 $ 3,493,347 $ 9,918,093 $ 3,143,102 $ 12,031,969 $ 4,133,800 $ 24,703,855 $ 3,324,746 Less, value of “Stock Awards” and “Option Awards” reported in Summary Compensation Table $ (10,319,000) $ (2,658,810) $ (8,314,056) $ (2,332,400) $ (10,382,549) $ (3,529,925) $ (23,019,000) $ (2,608,820) Plus, year-end fair value of outstanding and unvested equity awards granted in the year $ 6,585,800 $ 1,501,175 $ 6,288,252 $ 1,645,788 $ 8,222,939 $ 1,578,138 $ 49,944,000 $ 3,537,700 Plus, fair value as of vesting date of equity awards granted and vested in the year $ — $ — $ 595,920 $ — $ — $ — $ — $ — Plus (less), year over year change in fair value of outstanding and unvested equity awards granted in prior years $ (13,971,458) $ (570,234) $ (10,653,844) $ (492,469) $ (49,946,000) $ (2,754,375) $ 17,433,000 $ 2,015,691 Plus (less), change in fair value from last day of prior fiscal year to vesting date for equity awards granted in prior years that